Home
Sunovion

Sunovion Market Share Analysis for April 2026

improving health of people everywhere - innovative treatments, science, and tech to address patient needs in psychiatry, oncology, urology, women's health, rare diseases, and cell & gene therapy.

Health > Biotechnology and Pharmaceuticals

Domainsunovion.com

Year Founded2010

Employees5001 - 10000

Annual Revenue$200M - $500M

Sunovion

Sunovion (including company regionals)

sunovion.com

See more website traffic and engagement information

Sunovion Revenue up to April 2026 is 200M - 500M

revenue generated by Sunovion top domains

Sunovion top domains revenue over 3 years

Revenue for Sunovion top domains

sunovion.com200M - 500M

See more with Sales Intelligence

Total visits to Sunovion's top domains

Understand Sunovion market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

sunovion.com--

See more with Sales Intelligence

Avg. visit duration in Sunovion's top domains

Analyze Sunovion engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

sunovion.com--

See more with Sales Intelligence

Avg. pageviews on Sunovion's top domains

See how Sunovion keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

sunovion.com--

See more with Sales Intelligence

Sunovion top competitors by domain

Top similar sites in April 2026, ranked by their affinity

pfizer.comCompany NamePfizerEmployees> 10001HQUnited States, New York, New York CityAnnual revenue> $1BTotal visits2.2MHealth > Biotechnology and Pharmaceuticals

Top technologies used by Sunovion

These are the website technologies, by industry, used by Sunovion top domains

Audio Video Media (1)

YouTube

Conversion & Analytics (1)

Google Analytics

Email Services (1)

Symantec.cloud

Mobile (1)

Meta Viewport

More Technologies

2

See all

News & Signals from Sunovion

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPsychoGenics Inc. partners with Sunovion Pharmaceuticals Inc..Led by CEO and neuroscientist Dr. Emer Leahy, PsychoGenics has partnered with Sunovion Pharmaceuticals to develop an antipsychotic known as Ulotaront to treat schizophrenia, currently in Phase 3 clinical trials.

NewsSumitomo Pharma Co., Ltd merges with Sunovion Pharmaceuticals Inc..As part of efforts to achieve sustained growth after the loss of exclusivity for LATUDA®, one of the core products of the Sumitomo Pharma Group in the U.S., the Group will merge and combine seven of its subsidiaries in the U.S. into a single company, with Sunovion Pharmaceuticals Inc. as the remaining company:

NewsSunovion Pharmaceuticals Inc. decreased headcount by 360 on Jan 1st '22.Sunovion Pharmaceuticals Inc., a Marlborough-based subsidiary of Japanese drugmaker Sumitomo Dainippon Pharma Co. Ltd., will lay off 360 employees come January.